Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 339

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

Burnett, Alan K., Wheatley, Keith, Goldstone, Anthony H., Stevens, Richard F., Hann, Ian M., Rees, John H. K., Harrison, Georgina, the Medical Research Council Adult and Paediatric Working Parties·2002·British Journal of Haematology

Abstract

Summary. Patients under 55 years in the United Kingdom Medical Research Council Acute Myeloid Leukaemia 10 trial who entered complete remission were tissue typed (n = 1063). Four hundred and nineteen had a matched sibling donor and 644 had no match. When compared on a donor versus no donor basis the relapse risk was reduced in the donor arm (36%vs 52%; P = 0·001) and the disease‐free survival (DFS) improved (50%vs 42%; P = 0·01), but overall survival (OS) was not different (55%vs 50%; P = 0·1). Sixty‐one per cent of patients with a donor underwent transplantation. When patients were subdivided into risk groups based on cytogenetics alone or with the addition of blast response to course 1, a reduction in relapse risk was seen in all risk groups and in three age cohorts (0–14, 15–34 and 35+ years). Significant benefit in DFS was only seen in the intermediate‐risk cytogenetic group (50%vs 39%; P = 0·004). The OS benefit was only seen in intermediate‐risk patients (55%vs 44%; P = 0·02). The reduction in relapse risk in good‐risk patients was attributable to patients with t(15;17) and not to patients with t(8;21) or inv(16). Allogeneic transplantation given after intensive chemotherapy was able to reduce relapse in all risk and age groups. However, due to the competing effects of procedural mortality and an inferior response to chemotherapy if relapse does occur, there was a survival advantage only in patients of intermediate risk. This trial found no survival advantage in children, patients over 35 years or good‐risk disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2002.03724.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 339

Metadata

Authors
Burnett, A. K., Wheatley, K., Goldstone, A. H., Stevens, R. F., Hann, I. M., Rees, J. H. K., Harrison, G., & the Medical Research Council Adult and Paediatric Working Parties
Venue
British Journal of Haematology
Publisher
Wiley
Published
2002-07-25
Volume
118
Issue
2
Pages
385-400
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2041150576
Cited by
339
References
26
FWCI
9.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. https://app.cochat.ai/papers/10.1046/j.1365-2141.2002.03724.x
The paper
Burnett, A. K., Wheatley, K., Goldstone, A. H., Stevens, R. F., Hann, I. M., Rees, J. H. K., Harrison, G., & the Medical Research Council Adult and Paediatric Working Parties. (2002). The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2002.03724.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.